CDK inhibitors in clinical development for the treatment of cancer.
about
Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factorsSeliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myelomaSubstituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer ActivitiesMachine learning methods for prediction of CDK-inhibitorsTargeting CDKs with Roscovitine Increases Sensitivity to DNA Damaging Drugs of Human Osteosarcoma CellsRoscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenanceTargeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73.ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin ECell cycle molecules and vertebrate neuron death: E2F at the hub.Roscovitine inhibits CaV3.1 (T-type) channels by preferentially affecting closed-state inactivation.Targeting protein kinases in cancer therapy: a success?Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.Kinase selectivity profiling by inhibitor affinity chromatography.Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy.Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.Method to Assess Interactivity of Drugs with Nonparallel Concentration-Effect Relationships.MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1B.PNUTS knockdown potentiates the apoptotic effect of Roscovitine in breast and colon cancer cellsThe Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation.Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels.A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo.Structure-aided optimization of kinase inhibitors derived from alsterpaullone.Molecular modeling studies of 4,5-dihydro-1H-pyrazolo[4,3-h] quinazoline derivatives as potent CDK2/Cyclin a inhibitors using 3D-QSAR and docking.The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors.Gastric and pancreatic lesions in rats treated with a pan-CDK inhibitor.Molecular modelling on small molecular CDK2 inhibitors: an integrated approach using a combination of molecular docking, 3D-QSAR and pharmacophore modelling.Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.
P2860
Q24562983-AACA5EDB-32CA-4302-AA70-60189A66D2FAQ24669938-77A55A78-65CC-4F03-9CEC-D263C4B2D3BCQ27675842-91A40695-70AA-4284-9696-CAF88B5215B4Q28475771-BA7E7950-8C70-4382-B2DA-DC5FBA2B0B0AQ28554501-A09332D9-12BB-4019-A4C7-DD7275FD7DE9Q33786506-67516F2D-07FF-4C0F-A9B5-CF79BC8BB281Q34365839-AF239FD0-E368-4720-AB83-83131EBCAAADQ34756557-CB467E5D-03FA-4549-970D-C3CBE5362D29Q35447625-FD4E472A-80FE-4E96-A993-69A12430369BQ35597038-3D4E26A5-A313-416A-902D-5E6A6B8D105DQ35688524-E0D92959-CFB0-4DC5-AD72-E9E27D678514Q35987779-4E67B9A4-2AC0-41F7-B9E3-E2DA116B18F0Q36120794-F63D7133-2A5D-4F9E-A7B4-8C2BE9E8BBB2Q36168379-74A9D7CE-1B69-45AE-80BC-757123AD883DQ36296415-83CD4817-503D-437B-95C3-8A5855FB8F35Q36716750-25EA088F-1E2A-4D0E-8EE8-610A342104F8Q37162402-99C42ABA-D7D9-437B-BF13-B57F422CE0AEQ38248633-D53FA19E-F4C4-4B2E-B7EA-B9ED9D58EEAFQ38866872-B6BC71CB-81ED-40D7-BFC2-6FB0CEC25233Q39038019-3E089BF5-D5F2-45AE-B53C-D3A07667C55DQ39717914-75D4EB31-7B50-4481-AB51-8E96F8A1345FQ39905970-5F94F17B-0290-4053-B738-D9B4C4B58FF3Q40093407-EEB6C34A-F5A2-4D3E-B228-CA2D9405C934Q40219887-59399517-A246-4F15-B056-E9576AD59B2CQ40461072-09BE0A22-3867-40FB-A879-B3EA1BD4CE2EQ41239527-CD425FE5-1D40-4C5A-841B-C2014B89941CQ44678684-6F443868-F139-4C62-A1E7-98FBC75331B4Q46188282-2E071FF8-DCBB-4DDB-B5F0-7C2DA3086ED1Q47787864-22BD9C72-D358-4C26-BD96-8A4C490B2759Q51028667-1EEEE472-9CA2-4791-8E30-66F98FABF3CEQ53568928-C31D4D37-0394-4D02-A89C-B2583416D87A
P2860
CDK inhibitors in clinical development for the treatment of cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
CDK inhibitors in clinical development for the treatment of cancer.
@ast
CDK inhibitors in clinical development for the treatment of cancer.
@en
type
label
CDK inhibitors in clinical development for the treatment of cancer.
@ast
CDK inhibitors in clinical development for the treatment of cancer.
@en
prefLabel
CDK inhibitors in clinical development for the treatment of cancer.
@ast
CDK inhibitors in clinical development for the treatment of cancer.
@en
P2860
P1476
CDK inhibitors in clinical development for the treatment of cancer.
@en
P2093
Athos Gianella-Borradori
Peter M Fischer
P2860
P304
P356
10.1517/13543784.12.6.955
P407
P577
2003-06-01T00:00:00Z